Skip to main content
Premium Trial:

Request an Annual Quote

New Products: MolecularHealth's TreatmentMap Tests; Courtagen's Neurodevelopmental Dx

Premium

MolecularHealth has launched its TreatmentMap Targeted Panel, which covers 500 cancer-related genes, and the TreatmentMap Whole Exome test, which analyzes both somatic and germline mutations. Both tests also incorporate SafetyMap, a proprietary identification of drug target safety or resistance effects that uses the FDA’s Adverse Event Reporting System as an input for analysis. The tests are available for order in the US and Europe. MolecularHealth operates a CLIA-certified laboratory in The Woodlands, Texas.


Courtagen Life Sciences has launched two next-generation sequencing-based tests for neurodevelopmental disorders, developmental delay, intellectual disability, and autism spectrum disorder.

DevSeek screens around 100 genes known to cause neurodevelopmental disorders, including ASD, while DevAct screens for over 200 known treatable genetic disorders with the clinical presentation of ASD or other developmental disorders.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.